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Abstract
Several epidemiological studies indicate that moderate consumption of red wine is associated with
a lower incidence of dementia and Alzheimer's disease. Red wine is enriched in antioxidant
polyphenols with potential neuroprotective activities. Despite scepticism concerning the
bioavailability of these polyphenols, in vivo data have clearly demonstrated the neuroprotective
properties of the naturally occurring polyphenol resveratrol in rodent models for stress and
diseases. Furthermore, recent work in cell cultures and animal models has shed light on the
molecular mechanisms potentially involved in the beneficial effects of resveratrol intake against the
neurodegenerative process in Alzheimer's disease.
Background
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder leading to the most common form of demen-
tia in elderly people. Histopathological studies of the AD
brain revealed dramatic ultra-structural changes triggered
by two classical lesions, the senile plaques, mainly com-
posed of amyloid-β (Aβ) peptides, and the neurofibrillary
tangles, composed of hyperphosphorylated tau proteins
[1,2]. Although neurofibrillary tangles can occur inde-
pendently, and cause neuronal death in frontotemporal
dementia [3], the presence of both lesions in the neocor-
tex is essential to the diagnosis of AD. The pathogenesis of
the disease is complex and is driven by both environmen-
tal and genetic factors. Although most of the cases are spo-
radic with an obscure etiology, some forms of the disease
are inherited and several genes were found to be clearly
implicated in familial forms of the disease. The molecular
identification and characterization of different genes asso-
ciated with familial AD has provided strong support to the
so-called amyloid cascade hypothesis as a causative event
in the pathogenesis of AD [4]. This hypothesis states that
Aβ generated from deregulated proteolysis of the amyloid
precursor protein (APP) undergoes accelerated Aβ oli-
gomerization, fibril formation, and amyloid deposition
in a process that initiates the AD pathology [4].
In the past ten years, the large majority of the pharmaco-
logical research on AD has focused on understanding how
Aβ is generated from APP via β- and γ-secretase cleavages,
with the goal of designing specific inhibitors that will
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block Aβ production and the associated pathology. How-
ever, genetic and pharmacological approaches have
recently demonstrated that these enzymes have additional
molecular targets [5-7], and that secretase inhibitors can
cause severe mechanism-based side effects in vivo, casting
doubt over the potential of these therapeutic strategies [8].
In this context, approaches aimed at better understanding
the molecular pathways involved in Aβ clearance have
been gaining considerable attention over the last several
years [9].
Mechanisms of amyloid-β proteolytic clearance
A number of different receptor-mediated or endoproteo-
lytic pathways have been implicated in the process of Aβ
degradation [10]. The major enzymes responsible for Aβ
degradation in vivo are neprilysin (NEP), endothelin-con-
verting enzyme (ECE)-1 and ECE-2, insulin-degrading
enzyme (IDE), and plasmin. NEP, IDE, and ECEs are zinc
metalloendopeptidases that hydrolyze bioactive peptides
and several lines of evidence support a role for these
enzymes in Aβ degradation in cell cultures and animal
models (reviewed in [10]).
The plasminogen system
Plasmin is a serine protease released from the inactive
zymogen plasminogen upon cleavage by the tissue-type
plasminogen activator (t-PA) or by the urokinase-type
plasminogen activator (u-PA) (Figure 1) [11]. The plas-
minogen system is negatively controlled by the action of
soluble protein inhibitors that selectively bind plasmino-
gen or plasmin. These include the plasminogen activator
inhibitor-1 (PAI-1) and α2-plasmin inhibitor (α2-PI).
Plasmin is involved in many pathophysiological proc-
esses primarily through its ability to degrade components
of the extracellular matrix. In the brain, the plasminogen
system was shown to be involved in numerous functions,
including neuronal plasticity and long-term potentiation.
Importantly, polymorphisms in the u-PA gene have been
proposed to be associated with late-onset AD, suggesting
that deregulation of the plasminogen system may be asso-
ciated with the pathogenesis of the disease [12]. In addi-
tion, the t-PA-plasmin proteolytic cascade was found to
promote the clearance of Aβ in vivo in two different mouse
models of AD [13].
Red wine intake and Alzheimer's disease
No specific environmental risk factor has been definitively
identified as being associated with AD. However, the
potentially important role for diet in the causation or pre-
vention of AD is supported by several observations. For
instance, there is evidence that homocysteine-related vita-
mins, fats, and red wine consumption have a role in the
pathogenesis of AD [14]. The first study, published in
1997, reported that moderate to mild wine consumption
was associated with a low risk of AD [15]. Later, a nested
case-control study [16] and a cohort study [17] of individ-
uals aged 65 years and older confirmed that intake of
wine, but not other alcoholic drinks, was associated with
a low risk of dementia, including AD. Furthermore, a pro-
spective analysis of risk factors for AD in the Canadian
population determined that wine consumption was the
most protective variable against AD by reducing the risk of
AD by 50% [18]. Interestingly, wine intake in this popula-
tion was found to be even more protective than the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) [18].
Nevertheless, it should be noted that the notion that wine
intake – and more specifically red wine intake – lowers
AD risk is still controversial and remains to be clearly
demonstrated. In line with the epidemiological data,
however, Pasinetti and colleagues [19] have provided evi-
Schematic representation of the plasminogen system Figure 1
Schematic representation of the plasminogen system. The 
proenzyme plasminogen (Plg) is converted to the active ser-
ine protease plasmin (Plm) by the soluble or membrane 
bound urokinase-type plasminogen activator (u-PA). Mem-
brane bound u-PA binds to a cellular u-PA receptor (u-PAR). 
Inhibition of the plasminogen system may occur at the level 
of the plasminogen activators by plasminogen activator inhib-
itors (such as PAI-1), or at the level of plasmin by α2-plasmin 
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dence that moderate consumption of red wine lowers Aβ
levels and the associated neuropathology in the Tg2576
AD mouse model, implying that red wine intake may have
a beneficial effect against AD pathology by promoting
anti-amyloidogenic mechanisms.
Bioavailability and therapeutic potential of 
resveratrol
Resveratrol is a phytoalexin polyphenolic compound
occurring in grapes and wine. The levels of resveratrol
found in wine vary greatly, but is generally more abun-
dant in red grapes and red wine. Numerous studies per-
formed  ex vivo and in animal models have provided
information on the absorption, metabolism, and conse-
quent bioavailability of this polyphenol [20]. The oral
bioavailability of resveratrol is low due to rapid excretion
and extensive metabolism into various glucuronide and
sulfate conjugates of unknown potential biological activi-
ties. The major metabolites identified in the urine in
human after oral dosing of synthetic resveratrol are: res-
veratrol monosulphate, two isomeric forms of resveratrol
monoglucuronide, dihydroresveratrol monosulphate,
and dihydroresveratrol monoglucuronide. Total sulphate
conjugates account for more than one-third of the metab-
olites in the urine and total glucuronide conjugates repre-
sent about 20% [21]. These pharmacokinetic studies cast
doubt on the therapeutic potential of unmodified resver-
atrol. Nevertheless, in vivo data from several studies have
clearly demonstrated in various organisms that resveratrol
intake has protective properties against multiple illnesses,
including cancer, cardiovascular disease, and ischemia,
and was also found to confer resistance to stress and to
extend life span [22]. More recently, concordant studies
have also revealed the beneficial effect of resveratrol in
vivo  on energy metabolism in diseases such as diet-
induced obesity, insulin resistance, or aging-related syn-
dromes [23-25].
The antioxidant functions of resveratrol
Resveratrol is believed to afford strong antioxidant func-
tions in vitro and in cell culture models and, therefore, to
contribute to the cardio-protective, anti-inflammatory,
and neuroprotective properties of red wine intake [26].
Several lines of evidence underline the antioxidant and
neuroprotective effects of resveratrol. The polyphenol was
found to prevent membrane lipid peroxidation, internali-
zation of oxidized lipoprotein, and to reduce the toxic
effects of reactive oxygen intermediates in cultured cell
lines [27,28]. In addition, resveratrol delays Aβ-induced
toxicity in different neuronal culture models [29-31].
Nevertheless, the mechanism by which resveratrol is able
to achieve these effects remains to be clearly defined. Inde-
pendent biochemical approaches have, however, demon-
strated that the polyphenol has potent anti-
amyloidogenic and anti-fibril effects in vitro [32-35], sug-
gesting that resveratrol may act as an antioxidant by pre-
venting the formation of toxic Aβ oligomers and
protofibrillar intermediates.
Resveratrol, SIRT1, and amyloid pathology
Recent data provide interesting insights into the effect of
resveratrol on longevity and its potential protective role in
age-related human diseases, including AD. Resveratrol
mimics caloric restriction by extending the lifespan of dif-
ferent organisms via activation of deacetylases from the
sirtuin family [36]. Indeed, resveratrol binds to and acti-
vates the deacetylase activity of several sirtuin members,
including the mammalian ortholog, SIRT1, by lowering
the Michaelis constants of these enzymes [37]. Sirtuins are
nicotinamide adenine dinucleotide-dependent deacety-
lases required for the increased longevity due to caloric
restriction in yeast, Drosophila, and mice [36,38]. Sirtuins
deacetylate and control the activity of several transcription
factors, including peroxisome proliferator-activated recep-
tor (PPAR)γ cofactors, through a mechanism that regu-
lates lifespan in mice [39,40]. Importantly, Kim and
colleagues [41] recently reported that intracerebroven-
tricular injection of resveratrol reduced neurodegenera-
tion in the hippocampus and prevented learning
impairment in the p25 transgenic AD mouse model by a
mechanism that may involve a decrease in the acetylation
of known SIRT1 substrates, for example, peroxisome pro-
liferator-activated receptor gamma coactivator (PGC-1)α
and p53. In addition, caloric restriction was found to
attenuate amyloid deposition and Aβ-associated neuropa-
thology in different animal models [42,43], and SIRT1
activation may contribute to the anti-amyloidogenic
properties of this particular intervention [44,45]. In line
with these studies, resveratrol appears to be protective
against the dysregulation of energy homeostasis observed
in mouse models for metabolic syndromes by a mecha-
nism implicating the activation of SIRT1, PGC-1α, and
the energy sensor protein kinase AMPK (AMP-activated
protein kinase) [23-25].
Resveratrol, SIRT1, and plasmin activation
Our recent work indicates that resveratrol reduces Aβ
accumulation in cell cultures [46]. Resveratrol does not
inhibit Aβ production, since it has no effect on the Aβ-pro-
ducing enzymes β- and γ-secretases, but promotes instead
the proteolytic clearance of Aβ by a mechanism that does
not implicate NEP, ECE-1 and ECE-2, or IDE [46]. Several
groups have obtained evidence that resveratrol treatment
increases the expression of the plasminogen activators t-
PA and u-PA, suggesting that resveratrol could lead to
plasminogen endoproteolysis and plasmin activation
(Figure 1) [47,48]. Additional evidence indicates that
plasminogen activation is positively controlled by PPARγ
that appears to be a transcriptional target of SIRT1
[39,40,49]. This raises the intriguing possibility that res-BMC Neuroscience 2008, 9(Suppl 2):S6 http://www.biomedcentral.com/1471-2202/9/S2/S6
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veratrol controls plasmin activation by promoting SIRT1-
mediated transcription. This last observation may further
explain the anti-amyloidogenic effect of PPARγ activation
recently shown by several groups, including our own [50-
53]. Additional observations argue against a direct effect
of resveratrol on a protease degrading Aβ, but instead
point toward the implication of a transcriptional mecha-
nism in the regulation of Aβ degradation. There is, indeed,
no data indicating that resveratrol binds to and directly
stimulates a known Aβ-degrading protease. Moreover, the
long incubation periods required for resveratrol action
[46] clearly suggest the implication of gene expression reg-
ulation in the mechanism of Aβ clearance. Therefore, it is
possible that resveratrol acts by interacting with SIRT1-
mediated transcription in a pathway of Aβ degradation.
Conclusion
Although unmodified resveratrol appears to have a weak
bioavailability, several studies have clearly demonstrated
the in vivo neuroprotective properties of the red wine-
derived polyphenol, strongly supporting the notion that
natural metabolites of resveratrol may have biological
activities. Furthermore, recent findings have shed light on
the potential role of resveratrol in transcription- and deg-
radation-dependent anti-amyloidogenic mechanisms,
suggesting that natural metabolites or potent synthetic
analogues of resveratrol have a therapeutic potential in
AD.
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